Delisting risk
ONCO · NASDAQ · Biotechnology

Onconetix (ONCO)

Prostate-cancer diagnostics developer centered on the Proclarix blood test.

$0.6847
Pre-market−0.00 (−0.04%)
At close$0.6850(+4.93%)

Something off on this page? Send us feedback.

Next report
Nov 12, 2026
estimated · in 70 days
EPS estimate
−$45,050.00
Revenue estimate
$17.5K
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Jun '25Jun '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$6.40$1.06−$20.25−$31.25$12.58−$6.71−$1.28Pending
Estimate−$4,505.00−$45,050.00
Surprise+100.0%

RevenueReportedEstimate

Jun '25Jun '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported$712.0K$101.6K$106.5K$303.7K$303.6K$21.5K$17.1KPending
Estimate$17.1K$17.5K
Surprise0.0%

History

DateEstimateReportedSurprise
Nov 2026−$45,050.00
Aug 2026−$4,505.00−$1.28+100.0%
May 2026−$6.71
Mar 2026$12.58
Nov 2025−$31.25

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Aug 2025
Jun 2025
Jun 2025
Dec 2024
Aug 2024
May 2024
Apr 2024
Nov 2023
Oct 2023
May 2023
Mar 2023
Nov 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Mar 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 12, 2026−$45,050.00$17.5K
Aug 13, 2026−$4,505.00−$1.28+100.0%$17.1K$17.1K0.0%−1.0%
May 13, 2026−$6.71$21.5K+0.8%
Mar 12, 2026$12.58$303.6K−4.9%
Nov 13, 2025−$31.25$303.7K−6.2%

The latest year is open to everyone — the 17 quarters behind it read with an account.

Sign in
Aug 14, 2025
Jun 12, 2025
Jun 2, 2025
Dec 9, 2024
Aug 29, 2024
May 20, 2024
Apr 11, 2024
Nov 17, 2023
Oct 20, 2023
May 12, 2023
Mar 9, 2023
Nov 10, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Mar 31, 2021